In the absence of a submission from the holder of the marketing authorisation, temozolomide intravenous solution (Temodal®) cannot be endorsed for use within NHS Wales for the treatment of adult patients with newly-diagnosed glioblastoma multiforme concomitantly with radiotherapy (RT) and subsequently as monotherapy treatment; children from the age of three years, adolescents and adult patients with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy.